Sejtalapú

Sejtalapú is a Hungarian term used to describe approaches, products, or therapies that rely on living cells as the active component or delivery system. It encompasses a range of biomedical and biotechnological applications where cells themselves drive the effect, rather than purely chemical compounds.

In biomedicine, sejtalapú approaches include cell-based therapies such as stem cell therapies (for example mesenchymal stem cells for tissue repair) and cellular immunotherapies (such as CAR-T cell therapy) that modify or employ immune cells to treat disease. In vaccinology, cell-based vaccines use cultured cells to produce antigens. In regenerative medicine and tissue engineering, cells are combined with scaffolds or biomaterials to repair, replace, or restore damaged tissues. In research, cell-based models and organoids provide functional systems that more closely mimic human biology than traditional chemical models.

Manufacturing and safety considerations for sejtalapú products involve controlled cell culture, defined starting materials, and adherence to quality systems such as good manufacturing practices. Regulatory oversight focuses on safety, efficacy, and ethical aspects, with requirements varying by jurisdiction. Key safety concerns include immunogenic reactions, potential tumorigenicity, risk of contamination, and variability between cell batches. Development typically requires thorough preclinical testing and clinical trials to establish benefit and risk balance.

Advantages of sejtalapú approaches include the potential for targeted action, adaptive therapies, and long-term effects in some indications. Challenges encompass high production costs, complex logistics, ethical considerations for certain cell sources, scalability issues, and navigating regulatory pathways. Ongoing research aims to expand indications, improve safety profiles, and optimize manufacturing processes for broader clinical use.